You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Table TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available
Part (v) Inpatient clients by secondary drug and primary drug
| Secondary drug | Amphetamines | MDMA and other derivatives |
|---|---|---|
| Opioids | 357 | 5 |
| Cocaine | 111 | 14 |
| Cannabis | 1229 | 24 |
| Alcohol | 564 | 11 |
| Stimulants (other than cocaine) | 147 | 7 |
| Hypnotics and sedatives | 318 | 3 |
| Hallucinogens | 71 | 4 |
| Volatile | 19 | 2 |
| Other substances | 40 | 1 |
| Total number of citations | 2856 | 71 |
Notes
Clients may report one primary drug, but more than one secondary drug
Countries providing data are: BE, BG, CZ, DK, IE, GR, FR, LU, HU, NL, AT, RO, SK, FI, SE, UK, HR, TR.
The number of treatment clients in each country is listed in Table TDI-7.
See also 'General notes for interpreting data’ on the Explanatory notes and help page.
Source:
Reitox national reports 2011 — Table TDI by centre type.